RK-24466_COA_27177_MedChemExpress
3_种常用碳青霉烯类抗生素血药浓度UPLC-MS
3种常用碳青霉烯类抗生素血药浓度UPLC-MS/MS检测方法的建立Δ秦怡1＊，张瑞霞2，吕雅瑶2，翁莉莉1，张弋2 #（1.天津医科大学一中心临床学院，天津 300192；2.天津市第一中心医院药学部，天津 300192）中图分类号 R917；R978.1文献标志码 A 文章编号 1001-0408（2024）03-0343-05DOI 10.6039/j.issn.1001-0408.2024.03.14摘要目的建立3种临床常用碳青霉烯类抗生素——厄他培南（ETP）、亚胺培南（IPM）、美罗培南（MEM）血药浓度检测的超高效液相色谱-质谱联用（UPLC-MS/MS）法。
方法血浆样品经甲醇沉淀蛋白后，以3种抗生素的稳定性同位素（ETP-D4、IPM-D4、MEM-D6）为内标，采用ACQUITY UPLC BEH C18（2.1 mm×50 mm，1.7μm）色谱柱分离；流动相为98%乙腈+2%水+0.1%甲酸和98%水+2%乙腈+0.1%甲酸，梯度洗脱；流速为0.3 mL/min；柱温为40 ℃；采用正离子、多反应监测模式进行扫描分析。
结果该方法专属性良好，在ETP、IPM、MEM 0.2～200、0.1～100、0.1～100μg/mL范围内线性良好（r2≥0.993），批内、批间精密度和准确度良好（RE均≤5.14%，RSD均≤11.15%），基质效应、提取回收率较一致（RSD≤12.99%）。
结论本实验建立了一种可以同时定量ETP、IPM、MEM血药浓度的UPLC-MS/MS法，该方法样品前处理简单、检测时间短、所需样品量少，可满足临床需求。
关键词碳青霉烯类抗生素；超高效液相色谱-质谱联用；血药浓度；厄他培南；亚胺培南；美罗培南Establishment of UPLC-MS/MS method for the determination of plasma concentration of three common carbapenem antibioticsQIN Yi1，ZHANG Ruixia2，LYU Yayao2，WENG Lili1，ZHANG Yi2（1. First Central Clinical College of Tianjin Medical University，Tianjin 300192，China；2. Dept. of Pharmacy，Tianjin First Central Clinical Hospital，Tianjin 300192， China）ABSTRACT OBJECTIVE To establish a UPLC-MS/MS method for the determination of plasma concentration of three carbapenem antibiotics，i.e. ertapenem （ETP），imipenem （IPM）and meropenem （MEM）.METHODS After protein precipitation with methanol，the plasma samples were separated by ACQUITY UPLC BEH C18column （2.1mm×50mm，1.7μm）using stable isotopes of three antibiotics （ETP-D4，IPM-D4，MEM-D6）as the internal standard. The mobile phases were 98%acetonitrile +2% water +0.1%formic acid and 98%water +2%acetonitrile +0.1%formic acid，by gradient elution. The flow rate was 0.3mL/min and the column temperature was 40 ℃. Scanning analysis was performed in the positive ion and multiple reaction monitoring mode. RESULTS The method had good specificity，good linearity （r2≥0.993）in the range of 0.2-200，0.1-100and 0.1-100μg/mL of ETP，IPM and MEM，and good intra-batch and inter-batch precision and accuracy （all RE≤5.14%，all RSD≤11.15%），the matrix effect and extraction recovery were consistent （RSD≤12.99%）. CONCLUSIONS This study establishes the UPLC-MS/MS method to simultaneously quantify the plasma concentration of ETP，IPM and MEM. The method has the advantages of simple pretreatment， short detection time and small sample quantity to meet clinical requirement.KEYWORDS carbapenem antibiotics； UPLC-MS/MS； plasma concentration； ertapenem； imipenem； meropenem碳青霉烯类抗生素具有抗菌谱广、抗菌活性强、耐药率低的特点，已成为治疗重症感染的主要选择。
GeXP简介
•Alignment
•Call scores
•Heterozygote Detection
2013/11/12
6
GeXP荧光系统
•GeXP更适合检测突变/杂合子： •波长越长，干扰越少 ，背景噪音低;
•650nm •laser •750nm •laser
•无10％的cut off把噪音，不会把10％以上杂合子去掉；
•NO Interference •from biological materials
7
个体化用药检测
KIT-Exon9
PDGFRA-exon12
EGFR突变检测
肿瘤药物对应相关基因的检测
药物名称 易瑞沙/特罗凯类 检测基因
EGFR-Exon18 突变 EGFR-Exon19 突变 EGFR-Exon21 突变 EGFR-Exon20突变 C-KIT-Exon9 突变 C-KIT-Exon11 突变 C-KIT-Exon13 突变 C-KIT-Exon17 突变 PDGFRα-Exon12 PDGFRα-Exon18 CYP2D6*10 多态性 XRCC1-Exon6 多态性 XRCC1-Exon10 多态性 ERCC1-codon118 多态性 MRP2-Exon10 多态性 BRCA1-Exon2 (女)多态性 BRCA1-Exon20 (女)多态性 XPD基因多态性 UGT1A1 *6 多态性 UGT1A1*28 多态性 DPYD*2A 多态性
伊马替尼 他莫昔芬
铂类
伊立替康 氟脲嘧啶类
HBV分型、耐药突变检测
2、片段分析
• 只需要研究长度，不需要知道具体序列 • 分别率为1bp
片段分析应用
STR/SSR
融合基因，可变剪切体
ABT-737_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :ABT-737Catalog No. :HY-50907CAS No. :852808-04-91.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:ABT737; ABT 737Formula:C42H45ClN6O5S2Molecular Weight:813.43CAS No. :852808-04-94. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
乌腺金丝桃提取物在治疗支气管哮喘的药物中的应用[发明专利]
![乌腺金丝桃提取物在治疗支气管哮喘的药物中的应用[发明专利]](https://img.taocdn.com/s3/m/c3228de776c66137ef0619bc.png)
专利名称：乌腺金丝桃提取物在治疗支气管哮喘的药物中的应用
专利类型：发明专利
发明人：张同存,李秀梅,罗学刚,王楠,李坤,马宁,廖兴华
申请号：CN201210389884.5
申请日：20121015
公开号：CN102861115A
公开日：
20130109
专利内容由知识产权出版社提供
摘要：本发明涉及了一种乌腺金丝桃提取物在治疗支气管哮喘的药物中的应用，本发明通过动物实验说明：乌腺金丝桃提取物对磷酸组织胺和乙酰胆碱混和液喷雾致喘的小鼠具有明显的平喘作用，并且，对乙酰胆碱所引起的支气管收缩具有对抗作用；乌腺金丝桃提取物具有祛痰的作用；乌腺金丝桃提取物具有止咳的作用。
申请人：天津科技大学
地址：300457 天津市滨海新区经济技术开发区第13大街29号
国籍：CN
代理机构：天津盛理知识产权代理有限公司
代理人：王来佳
更多信息请下载全文后查看。
一种辅助诊断糖尿病的检测试剂盒及其使用方法[发明专利]
![一种辅助诊断糖尿病的检测试剂盒及其使用方法[发明专利]](https://img.taocdn.com/s3/m/6184445869dc5022abea0063.png)
专利名称：一种辅助诊断糖尿病的检测试剂盒及其使用方法专利类型：发明专利
发明人：段世伟,汤琳琳,麦一峰,叶孟
申请号：CN201410214173.3
申请日：20140520
公开号：CN104073556A
公开日：
20141001
专利内容由知识产权出版社提供
摘要：本发明公开了一种辅助诊断糖尿病的检测试剂盒，所述的检测试剂盒包含用于检测NFKBIE 基因、CD36基因及ADIPOQ基因单核苷酸多态性的引物，所述的单核苷酸多态性分别为
rs2233424、rs1194182和rs266729；其通过将检测试剂盒的引物对样品DNA进行PCR扩增，并对PCR扩增产物用荧光定量PCR仪分析熔解曲线，再将熔解曲线与标准熔解曲线进行比较，对比PCR扩增产物的Tm值，获得相应的基因分型结果。
本检测试剂盒可以辅助检测、预测受试者的糖尿病，检测方法简单，检测效率高，针对性强，从而能够促进糖尿病的早期预防和为用药治疗提供参考。
申请人：宁波大学
地址：315211 浙江省宁波市江北区风华路818号宁波大学医学院王长来楼A306
国籍：CN
代理机构：宁波市天晟知识产权代理有限公司
代理人：张文忠
更多信息请下载全文后查看。
曲美布汀药物对映体的液相色谱分离方法[发明专利]
![曲美布汀药物对映体的液相色谱分离方法[发明专利]](https://img.taocdn.com/s3/m/1dc3bed267ec102de3bd8982.png)
专利名称：曲美布汀药物对映体的液相色谱分离方法专利类型：发明专利
发明人：王来来,吕士杰,李树本
申请号：CN99126584.X
申请日：19991218
公开号：CN1258003A
公开日：
20000628
专利内容由知识产权出版社提供
摘要：本发明公开了一种曲美布汀药物对映体的液相色谱分离方法。
涂敷15%(质量)三(4－甲基苯甲酸)纤维素酯于大孔硅胶担体上,制备手性填料,湿法装填液相色谱柱,直接分离曲美布汀对映体。
洗脱液为正己烷/异丙醇(v/v)。
该方法使用的色谱担体价格较低,洗脱液为有机溶剂,在制备曲美布汀药物对映体时较易除去。
申请人：中国科学院兰州化学物理研究所
地址：730000 甘肃省兰州市城关区天水路342号
国籍：CN
代理机构：中国科学院兰州专利事务所
代理人：方晓佳
更多信息请下载全文后查看。
中药白及抑制酪氨酸酶及清除DPPH自由基的有效部位筛选及其制备工艺考察
中药白及抑制酪氨酸酶及清除DPPH自由基的有效部位筛选及其制备工艺考察陈美君;刘珈羽;李峰庆;陈鸿平;刘友平【期刊名称】《成都中医药大学学报》【年(卷),期】2017(40)2【摘要】目的:对白及不同提取物的抗氧化活性和对酪氨酸酶的抑制作用进行考察,筛选具有抗氧化及美白作用的功效部位,为白及的综合利用开发提供依据。
方法:采用水、70%乙醇、70%乙醇提取后水提等提取方式分别对白及进行回流提取,酪氨酸酶抑制法及DPPH自由基清除试验对各提取部位进行相关活性比较。
以酪氨酸酶抑制率及DPPH自由基的清除率为指标,对醇提浓度及具体制备工艺进行考察。
结果:白及水提物具有促进酪氨酸酶活性作用(-96.78%),其作用随反应时间延长而减弱,白及醇提物对酪氨酸酶具有良好的抑制率(68.36%),而醇提后水提物对酪氨酸酶呈现出先抑制后促进的作用,而后促进作用减弱;白及醇提物与水提物具有一定的清除DPPH自由基能力,其中醇提物抗氧化能力较高,为37.13%,而醇提水提物有增强自由基活性作用(为-43.73%)。
综上结果得出,白及醇提物对酪氨酸酶具有良好的抑制作用,对DPPH自由基具有一定的清除作用。
因此对醇提部位进行提取浓度、用量及提取时间、次数的考察,结果以95%乙醇,用量为100倍,提取时间为2 h,共提取1次,所得提取物的酪氨酸酶抑制率及DPPH自由基清除率较高。
结论:白及具有一定的抗氧化及美白功效,其中具体活性成分尚需进一步研究。
【总页数】5页(P15-19)【关键词】白及;酪氨酸酶抑制率;DPPH自由基清除率;制备工艺【作者】陈美君;刘珈羽;李峰庆;陈鸿平;刘友平【作者单位】成都中医药大学【正文语种】中文【中图分类】R282.71;R283【相关文献】1.不同豆浆制备工艺活性成分与DPPH自由基清除能力比较研究 [J], 于寒松;张伟;陈今朝;胡耀辉2.膜分离制取可溶性菜籽蛋白及其对DPPH自由基的清除作用 [J], 严梅荣;王丹丹;胡蓉;鞠兴荣3.白木香果皮提取物清除DPPH自由基能力及抑制酪氨酸酶活性的研究 [J], 李浩华;章卫民;陈玉婵;高晓霞;严寒静4.DPPH自由基清除法筛选当归芍药散抗氧化活性有效部位 [J], 曾宇;江滨;马世平;曾元儿;张现涛;刘素珍;叶婷婷5.溶剂—超声波法提取石榴皮中总多酚的工艺考察及体外清除DPPH自由基的研究 [J], 周帆;季甲;韦胜艳因版权原因，仅展示原文概要，查看原文内容请购买。